New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:58 EDTAGN, VRXAllergan has many other strategic options, says BMO Capital
After meeting with Allergan's (AGN) management, BMO Capital says that the company has many strategic options other than the takeover bid from Valeant (VRX). The firm thinks that Allergan's outlook as a standalone company is strong, and it believes there is less than a 50% chance that Valeant will acquire Allergan. The firm keeps an Outperform rating on Allergan.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 17, 2014
09:16 EDTAGNActavis confirms deal to acquire Allergan for $219 in cash, stock
Subscribe for More Information
09:15 EDTAGNActavis confirms deal to acquire Allergan for $219 in cash and shares
Subscribe for More Information
09:10 EDTAGNActavis buying Allergan for $219 per share, CNBC reports
06:05 EDTAGN, VRXActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
14:02 EDTVRX, AGNAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
November 14, 2014
09:38 EDTVRXJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).
November 13, 2014
09:33 EDTVRXZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
07:23 EDTVRX, AGNValeant wooing doctors ahead of hoped for Allergan acquisition, WSJ says
Subscribe for More Information
November 12, 2014
16:53 EDTAGNAllergan receives FDA approval for new styles of NATRELLE 410
Subscribe for More Information
10:09 EDTVRX, AGNActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
10:01 EDTAGNActavis in talks to buy Allergan for $60B, more than $200/share Bloomberg says
Actavis (ACT) is said to seek to pay about $200 per share, but Allergan (AGN) seeks about $210 per share, according to Bloomberg.
07:01 EDTAGNAllergan announces approval of amendments to company bylaws
Subscribe for More Information
06:22 EDTAGN, VRXZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 11, 2014
16:24 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
15:46 EDTAGN, VRXPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
08:32 EDTAGN, VRXValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
November 9, 2014
13:26 EDTVRX, AGNAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
November 7, 2014
17:05 EDTVRXValeant sends open letter to physician customers
Subscribe for More Information
14:56 EDTVRX, AGNAllergan says Valeant offers to date inadequate, would consider increased bid
Subscribe for More Information
09:49 EDTAGN, VRXAckman says Allergan 'tipping scales' in Actavis’ favor, disadvantaging Valeant
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use